| Identification | Back Directory | [Name]
[1,1′-Biphenyl]-3-sulfonyl fluoride, 4′-[[[(1,4-dihydro-6-methyl-4-oxo-1-phenyl-3-pyridazinyl)carbonyl]amino]methyl]-3′,5′-difluoro- | [CAS]
3033748-20-5 | [Synonyms]
[1,1′-Biphenyl]-3-sulfonyl fluoride, 4′-[[[(1,4-dihydro-6-methyl-4-oxo-1-phenyl-3-pyridazinyl)carbonyl]amino]methyl]-3′,5′-difluoro- | [Molecular Formula]
C25H18F3N3O4S | [MOL File]
3033748-20-5.mol | [Molecular Weight]
513.49 |
| Chemical Properties | Back Directory | [density ]
1.41±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [solubility ]
Acetonitrile: Soluble
DMSO: Soluble | [form ]
Solid | [pka]
6.68±0.20(predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Anticancer agent 126 (compound 12) is a WDR5 inhibitor with anticancer effects. Anticancer agent 126 disrupts WDR5-MYC interaction in cells and reduce MYC target gene expression[1]. | [References]
[1] Jian Ding, et al. Discovery and Structure-Based Design of Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Interaction. J Med Chem. 2023 Jun 22;66(12):8310-8323. DOI:10.1021/acs.jmedchem.3c00787 |
|
|